4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announced that it has successfully secured €15 million in its second closing with participation from private investors.
With this funding round, 4P-Pharma’s shareholders renew their confidence in the company’s drug regeneration model for untreated serious diseases. They welcome the entry of Phase 2 clinical development of the two first 4P-Pharma SPVs, which underscores the robust potential of the company’s business model.
This additional shareholders’ financial backing is a boost that will enable 4P-Pharma to deploy its drug regeneration model triggered by an unrevealed match between established MOA with unexplored targeting of disease biology, paving the way for developing first-in-class therapies. And this cashflow reserve ensures financial stability and operational agility to engage actively external growth opportunities through M&A and licensing-in and accelerate 4P-Pharma’s startup studio model for building a balanced pipeline towards the commercial stage.
KEY QUOTES:
“As CEO of 4P-Pharma, I am pleased with the renewed trust of our investors placed in our scientific and development approach year after year. This financial endorsement underscores our significant progress over the past decade. It attests to the strength of our model for delivering first-in-class treatments for people suffering from untreated serious diseases.”
“After a decade of existence, 4P-Pharma is opening a novel turning point of its growth. This successful capital-secure will enable us to push forward our patient-centric vision transforming science into success stories for the best for the patients and the whole medical community.”
- Revital Rattenbach, CEO of 4P-Pharma
